Learn More - WordPress theme developed by myThem.es

New drug treatment for relief of noninfectious diarrhea in HIV+ patients

By: Out In Jersey

Napo Pharmaceuticals announced the availability of Mytesi (crofelemer), the only antidiarrheal studied in and FDA-approved for the relief of diarrhea in HIV+ patients. Previously marketed as Fulyzaq, the product includes the unveiling of the Mytesi Copay Savings Program and NapoCares™ Patient Assistance Program to provide people living with HIV/AIDS with broad, affordable access to the drug

Read More
Napo Pharmaceuticals Launches Mytesi (crofelemer) as the Only FDA-Approved Treatment for Relief of Noninfectious Diarrhea in HIV+ Patients

Napo Pharmaceuticals Launches Mytesi (crofelemer) as the Only FDA-Approved Treatment for Relief of Noninfectious Diarrhea in HIV+ Patients

Napo Pharmaceuticals, Inc., announced today the launch and general availability of Mytesi (crofelemer), the only antidiarrheal studied in and FDA-approved for the relief of diarrhea in HIV+ patients.1 Previously marketed as Fulyzaq, the product launch under the Mytesi brand importantly includes the unveiling of the Mytesi Copay Savings Program and NapoCares™ Patient Assistance Program to provide people living with HIV/AIDS with broad, affordable access to the drug.

Read More
Optimization WordPress Plugins & Solutions by W3 EDGE